晚期肺癌中ALK活化型改变与靶向治疗的研究进展
Aojiao WEI, Bo JIANG, Yurong HUANG, Mengyun LIU, Jing YAN, Yuanyuan ZHAO, Wenjie HE · 2024
Read 晚期肺癌中ALK活化型改变与靶向治疗的研究进展 by Aojiao WEI, Bo JIANG, Yurong HUANG, Mengyun LIU, Jing YAN, Yuanyuan ZHAO, Wenjie HE (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11839494.txt.
Description
Wei and co-authors review gene changes in a growth switch tied to advanced lung cancer, in a 2024 paper. The switch, known by the short name ALK, can break in several ways: a letter swap, extra copies, or a fusion with another gene. Fusion is the most common break and opens the door to targeted pills.
Those pills stretch survival for patients whose tumors carry the change, the review notes. Yet each break kind answers therapy in its own way, so naming the kind matters. The authors sort the variants, sum up gains in targeted care for each, and point to open ends. Future work should sharpen tests and widen drug reach, they urge.
Catalog record
| CREATOR | Aojiao WEI, Bo JIANG, Yurong HUANG, Mengyun LIU, Jing YAN, Yuanyuan ZHAO, Wenjie HE |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |